The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: The results of a randomized, double-blind, active-controlled study

European Heart Journal

Volumn 38, Issue 44, 2017, Pages 3308-3317

  Schmieder, Roland E ^a   Wagner, Frank ^b   Mayr, Michael ^c   Delles, Christian ^d   Ott, Christian ^a   Keicher, Christian ^b   Hrabak Paar, Maja ^c,e   Heye, Tobias ^c   Aichner, Solveig ^c   Khder, Yasser ^f   Yates, Denise ^g   Albrecht, Diego ^f   Langenickel, Thomas ^f   Freyhardt, Patrick ^b   Janka, Rolf ^a   Bremerich, Jens ^c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e KBC Zagreb   (Croatia)

^f NOVARTIS PHARMA AG   (Switzerland)

^g NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Angiotensin; Arterial stiffness; Heart failure; Hypertension; Left ventricular hypertrophy; Neprilysin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ENKEPHALINASE INHIBITOR; OLMESARTAN; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; MEMBRANE METALLOENDOPEPTIDASE; TETRAZOLE DERIVATIVE;

ADULT; ARTERIAL STIFFNESS; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; ELEVATED BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HEART DILATATION; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VASCULAR REMODELING; AORTA; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MAGNETIC RESONANCE ANGIOGRAPHY; MEDICATION COMPLIANCE; MULTICENTER STUDY; PATHOPHYSIOLOGY; THORACIC AORTA;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; AORTA; AORTA, THORACIC; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ESSENTIAL HYPERTENSION; FEMALE; HEART FAILURE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; IMIDAZOLES; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEPRILYSIN; TETRAZOLES; VASCULAR STIFFNESS; VENTRICULAR REMODELING;

EID: 85045943801     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx525     Document Type: Article

References (35)

1. Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH. Aortic stiffness: current understanding and future directions. J Am Coll Cardiol 2011;57:1511-1522.
2. Steppan J, Barodka V, Berkowitz DE, Nyhan D. Vascular stiffness and increased pulse pressure in the aging cardiovascular system. Cardiol Res Pract 2011;2011:263585.
3. Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, Folsom AR. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008;52:2148-2155.
4. Sutton-Tyrrell K, Najjar SS, Boudreau RM, Venkitachalam L, Kupelian V, Simonsick EM, Havlik R, Lakatta EG, Spurgeon H, Kritchevsky S, Pahor M, Bauer D, Newman A; Health ABC Study. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005;111:3384-3390.
5. Redheuil A, Wu CO, Kachenoura N, Ohyama Y, Yan RT, Bertoni AG, Hundley GW, Duprez DA, Jacobs DR Jr, Daniels LB, Darwin C, Sibley C, Bluemke DA, Lima JA. Proximal aortic distensibility is an independent predictor of all-cause mortality and incident CV events. the MESA study. J Am Coll Cardiol 2014;64:2619-2629.
6. Tsao CW, Gona PN, Salton CJ, Chuang ML, Levy D, Manning WJ, O'Donnell CJ. Left ventricular structure and risk of cardiovascular events: a Framingham Heart Study cardiac magnetic resonance study. J Am Heart Assoc 2015;4:e002188.
7. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, Vita JA, Levy D, Benjamin EJ. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010;121:505-511.
8. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de BP, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryden L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de BP, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-2219.
9. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-352.
10. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, Poisa P, Rizzoni D, Castellano M, Agabiti-Rosei E. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004;43:731-738.
11. Schiffrin EL. Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature. J Cell Mol Med 2010;14:1018-1029.
12. Ong KT, Delerme S, Pannier B, Safar ME, Benetos A, Laurent S, Boutouyrie P. Investigators. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J Hypertens 2011;29:1034-1042.
13. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110:1456-1462.
14. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41-46.
15. Heeneman S, Sluimer JC, Daemen MJ. Angiotensin-converting enzyme and vascular remodeling. Circ Res 2007;101:441-454.
16. Benetos A, Gautier S, Lafleche A, Topouchian J, Frangin G, Girerd X, Sissmann J, Safar ME. Blockade of angiotensin II type 1 receptors: effect on carotid and radial artery structure and function in hypertensive humans. J Vasc Res 2000;37:8-15; discussion 68-70.
17. Petrovic I, Petrovic D, Vukovic N, Zivanovic B, Dragicevic J, Vasiljevic Z, Babic R. Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res 2005;33(Suppl. 1): 39A-49A.
18. Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S; Investigators OT. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the ongoing Telmisartan alone and in combination with Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular disease. Circulation 2009;120:1380-1389.
19. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force M. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-2200.
20. Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J 2015;36:1967-1973.
21. Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H, Frampton C. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11:407-416.
22. McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol 2003;43:329-332.
23. Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607-613.
24. Mitchell GF, Izzo JL Jr, Lacourciere Y, Ouellet JP, Neutel J, Qian C, Kerwin LJ, Block AJ, Pfeffer MA. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation 2002;105:2955-2961.
25. Minguet J, Sutton G, Ferrero C, Gomez T, Bramlage P. LCZ696: a new paradigm for the treatment of heart failure? Expert Opin Pharmacother 2015;16:435-446.
26. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; Investigators P-H. Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
27. Asmar R, Vol S, Brisac AM, Tichet J, Topouchian J. Reference values for clinic pulse pressure in a nonselected population. Am J Hypertens 2001;14:415-418.
28. Sakuma H, Fujita N, Foo TK, Caputo GR, Nelson SJ, Hartiala J, Shimakawa A, Higgins CB. Evaluation of left ventricular volume and mass with breath-hold cine MR imaging. Radiology 1993;188:377-380.
29. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlof B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350-2356.
30. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S; Heart Outcomes Prevention Evaluation I. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001;104:1615-1621.
31. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Bloodpressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255-1266.
32. Jhund PS, Claggett B, Packer M, Zile MR, Voors AA, Pieske B, Lefkowitz M, Shi V, Bransford T, McMurray JJ, Solomon SD. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail 2014;16:671-677.
33. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007;369:1208-1219.
34. Ichihara A, Kaneshiro Y, Sakoda M, Takemitsu T, Itoh H. Add-on amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin receptor blocker. J Cardiovasc Pharmacol 2007;49:161-166.
35. Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, Guo W. Effects of sacubitril/valsartan versus Olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study. Hypertension 2017;69:411-420.